Clinical Trails

A new combination therapy for advanced urothelial cancer shows promising results, according to the Phase 2 TROPION-PanTumor03 trial. Datopotamab deruxtecan (Dato-DXd), a TROP2-targeted antibody-drug conjugate, was combined with rilvegostomig, a bispecific antibody against PD-1 and TIGIT, to enhance antitumor activity. In cisplatin-ineligible, first-line patients (n=22), the confirmed objective response rate (ORR) was 68.2%, with a […]

In Phase II study for extensive-stage small-cell lung cancer (ES-SCLC), the novel intercalated administration of the anti-PD-L1 inhibitor avelumab with platinum-etoposide chemotherapy (avelumab started after cycle 2) did not meet the primary endpoint of a 25% one-year progression-free survival (PFS), achieving 12.7% (median PFS: 5.8 months). Despite this, the treatment demonstrated high anti-tumor activity with an Objective Response

Large B-cell lymphoma (LBCL) is the most common aggressive non-Hodgkin lymphoma, with about 60% of patients cured by first-line therapy. Relapsed or refractory (R/R) patients have poor outcomes, with median survival around 6.3 months. Autologous CD19 CAR T-cell therapies help some patients but are limited by manufacturing delays, disease aggressiveness, and access barriers. Cemacabtagene ansegedleucel

Clinical trials are exploring a range of innovative therapies for bladder cancer, aiming to improve outcomes while preserving the bladder. Intravesical and Targeted Therapies: Oncolytic viruses like cretostimogene grenadenorepvec and EG-70 are designed to selectively kill cancer cells and activate the immune system. Novel drug delivery systems, such as TAR-210, release chemotherapy (e.g., erdafitinib) over time